Metir (LSE:MET), the York-based water and environmental testing technology company, has warned that full-year revenue for 2026 will come in below last year's level after half-year results published on 28 September 2026 showed sales falling by around 60%. The company has said it is determined to complete a fundraise in the short term, while it continues to pursue longer-term opportunities in testing for so-called forever chemicals and waterborne pathogens.

What the company does

Metir, which adopted its current name in February 2025, operates two divisions. Modern Water sells the Microtox range of toxicity testing instruments and reagents used to monitor water quality, while Microsaic Systems is developing mobile detection technology for per- and polyfluoroalkyl substances, commonly known as PFAS. The group sells through a growing distributor network, with recent appointments covering markets including Saudi Arabia, Bahrain, Malaysia, the UAE and Egypt.

Latest developments

Revenue for the six months to 30 June 2026 was about £367,000, down from £919,000 a year earlier and below management's expectations. The pre-tax loss widened to £542,000 from £304,000. Metir attributed the shortfall to lower equipment sales and a temporary pause in production of its sulphate reducing bacteria testing kits, which are being redesigned. Executive chairman and chief executive Bob Moore said the board expects 2026 revenue to be lower than in 2025.

The company's flagship project in Qatar, where 27 continuous toxicity monitors were installed across Doha's water pumping network, has also been affected by regional conflict, which delayed final handover of the first phase. A further payment of £198,000 is due within 60 days of handover, and a possible second-phase tender remains contingent on the first phase operating fully.

There has been progress elsewhere. Metir made its first commercial PFAS platform sale, to Nasdaq-listed Veralto, in June 2026 and agreed to take sole ownership of the underlying intellectual property. It also signed a memorandum of understanding with Portsmouth Aviation in July. Work with Aptamer Group on a detector for the parasite cryptosporidium has moved into a second phase, with commercialisation targeted for early 2027.

Financial picture

For the year to 31 December 2025, published on 7 July 2026, revenue rose to £1.44m from £0.23m and the loss before tax narrowed to £0.87m. Cash stood at £1.06m at the year-end following two fundraisings in 2025. However, the directors flagged a material uncertainty over going concern, noting that forecasts depend on raising at least £0.5m of additional working capital alongside cost-saving measures. Trading in the shares was briefly suspended on 1 July 2026 and restored on 7 July, the day final results were published. Metir does not pay a dividend.

Sector and index context

Demand for water quality monitoring is being driven by tighter regulation and growing public concern over contaminants such as PFAS. Metir is, however, one of the smallest companies on the FTSE AIM All Share Index, and micro-cap technology businesses with limited revenue often face volatile share prices and expensive capital.

Key risks

The most immediate risk is funding, given the going concern warning and the need for new capital. Revenue remains lumpy and heavily dependent on a small number of projects and production capacity, which has previously been constrained by outsourced manufacturing. Geopolitical disruption in the Gulf could delay further Qatar income, and new technologies such as the PFAS platform and pathogen detector carry development and commercial risk.

What to watch next

Investors will be watching for the outcome of the planned fundraise, confirmation of the Qatar handover and final payment, the restart of sulphate reducing bacteria kit production, further PFAS orders and progress on the pathogen detector ahead of its planned 2027 launch.